Please assess the completion status of the following clinical trial:

Trial Title: Revaccination With PNEUMOVAX(TM) 23 in Older Adults (V110-007)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Postmenopausal or negative urine pregnancy test if female~* No fever on the day of vaccination~Exclusion Criteria:~* History of allergy to vaccine components~* History of pneumococcal disease~* Received any live virus vaccination within 4 weeks prior to study start~* Received any inactivated vaccination within 7 days prior to study start~* Received any blood products within 5 months prior to study start~* Participated in an investigational drug or vaccine study in the past 30 days~* Received immunosuppressive therapy~* Patient has an immune deficiency

- Gender: ALL
- Minimum Age: 59 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- 1st Revaccination Group (Type: EXPERIMENTAL): None
- 2nd Revaccination Group (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).